Commonwealth extends global reach with new deal

Commonwealth Biotechnologies Inc. has struck a deal with PharmAust Ltd. to form a strategic alliance and client referral agreement under which they will co-market their services to the life sciences industry.

Register for free to listen to this article
Listen with Speechify
RICHMOND, Va.—Commonwealth Biotechnologies Inc. has struck a deal with PharmAust Ltd., an Australia-based biotech services company, to form a strategic alli­ance and client referral agreement under which they will co-market their services to the life sciences industry. The agreement will pro­vide for ready access of customers to the largely complementary com­bined capabilities of the two orga­nizations, and reportedly enable better overall solutions to be devel­oped on the demanding times­cales required by clients in the life sciences industry. The extended geographic reach brought about by this partnership also will offer a new solution for multinational companies with global service requirements.
"This is one of those true win-win relationships where each company stands to benefit enor­mously from the added technol­ogy offerings and extended global reach. In particular, CBI will now have access to the large and rap­idly growing market in the Pacific Rim while PharmAust will be able to offer its drug discovery ser­vices in medicinal chemistry and peptide technologies to the CBI's large client base," says Richard J. Freer, chairman and COO of CBI. "Access to PharmAust's direct sales force is also a real bonus. They are highly seasoned and, more importantly, are well versed in selling services such as those offered by CBI," he adds.
PharmAust's managing direc­tor, Dr. Paul D'Sylva notes, "This alliance is in line with PharmAust's strategy to work with high-quality partners to enhance the range and depth of our product and service offerings to the global drug discov­ery industry."
"The integration and co-mar­keting of PharmAust and CBI's preclinical capabilities offers the industry a single-point of service for early-stage drug discovery and development. This agreement rep­resents an important first step in what PharmAust considers to be a strategically important relation­ship going forward," Dr. D'Sylva says.
Commonwealth is a solutions provider to the global biotechnol­ogy industry, academic institu­tions, government agencies, and pharmaceutical companies, offer­ing broad-ranging expertise and a complete array of analytical and synthetic chemistries and biophys­ical analysis technologies.
PharmAust, based in Perth, Western Australia, is a vertically integrated pharmaceutical group of companies involved in a range of activities from contract drug dis­covery and development to man­ufacturing, sales and marketing of healthcare and pharmaceutical products.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue